Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01681264 · ClinicalTrials.gov registry record · Phase 4
Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 137
- Enrollment target
NCT01681264: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.
NCT01681264 is a Phase 4 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 137 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01681264, a Phase 4 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 137 participants
- Enrollment target
Study Summary
Dual medication (guanfacine and morphine) as a standard treatment for chronic pain.
Interventions
- DRUG Placebo
- DRUG Morphine
- DRUG Guanfacine 1mg
- DRUG Guanfacine 2mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2014-09 |
| Est. Completion | 2023-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01681264
The ClinicalTrials.gov registry entry for NCT01681264 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01681264 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01681264 about?
NCT01681264 is a clinical study titled "Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance". Dual medication (guanfacine and morphine) as a standard treatment for chronic pain.
What is the current status of trial NCT01681264?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 137 participants. The study started on 2014-09. Estimated completion is 2023-12.
What interventions are being tested in trial NCT01681264?
The interventions under investigation include: Placebo (DRUG), Morphine (DRUG), Guanfacine 1mg (DRUG), Guanfacine 2mg (DRUG).
Who is sponsoring clinical trial NCT01681264?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.